Harrow reaffirms FY25 revenue view $270M-$280M, consensus $271.18M

Mark Baum, Chief Executive Officer of Harrow (HROW), stated, “Our team delivered another year of strong growth in 2025, supported by positive demand trends across our key revenue-driving products, as well as meaningful progress with other parts of our portfolio, all of which we look forward to discussing further in early March when we release our full year 2025 financial results. As we begin what we believe will be another record-setting year of growth, after many years operating under two separate commercial organizations, the OneHarrow initiative will provide greater focus, tighter alignment, and a unified effort, driving disciplined and coordinated execution across a single organization. In addition, we have initiated hiring to double the sales force supporting VEVYE and the surgical sales force supporting TRIESENCE, both driven by growing momentum and customer interest in these cornerstone products in our portfolio. We are also excited to expand IHEEZO’s focus to a targeted, separately reimbursed office-based procedures market, which we estimate exceeds 2.5i million procedures annually. This expansion of IHEEZO establishes it as a foundational tool to improve everyday ophthalmic care and vastly increases the addressable market our team is covering.”